Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D005998:Glycine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000494:pharmacology; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood* / Q000517:prevention & control; D010880:Piperidines / Q000008:administration & dosage* / Q000494:pharmacology; D011237:Predictive Value of Tests; D012307:Risk Factors; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D019851:Thrombophilia / Q000097:blood; D017211:Treatment Failure; D016896:Treatment Outcome; D020107:Troponin T / Q000097:blood
D015415:Biomarkers; D010880:Piperidines; D020107:Troponin T; C099871:inogatran; D006493:Heparin; D013917:Thrombin; D005998:Glycine